You are here

SBIR Phase I: Plasma Thermograms for Disease Detection and Monitoring

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 0912660
Agency Tracking Number: 0912660
Amount: $99,801.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: BC
Solicitation Number: NSF 08-548
Timeline
Solicitation Year: N/A
Award Year: 2009
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
400 W Market St, Ste 1800
Louisville, KY 40202
United States
DUNS: 825146975
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Greg Brewood
 DPhil
 (503) 725-2350
 gbrewood@pdxbio.com
Business Contact
 Greg Brewood
Title: DPhil
Phone: (503) 725-2350
Email: gbrewood@pdxbio.com
Research Institution
N/A
Abstract

This Small Business Innovation Research Phase I project is to develop and commercialize a powerful new diagnostic assay platform for quantitative analysis of plasma from human blood using Differential Scanning Calorimetry. The platform will form the basis for generating novel high-throughput diagnostic assays requiring minimal sample handling and processing that can be performed in an hour on a single drop of blood. Output is in the form of a melting curve, or thermogram. Each thermogram provides a highly sensitive and specific signature for a variety of disease states including various cancers, auto-immune and infectious diseases. Thermograms establish a powerful new vista from which to view plasma diagnostics and provide an excellent complement to more traditional plasma diagnostic methods (electrophoresis and mass spectrometry) that separate plasma/serum proteins based on their mass and charge. The broader impacts of this research stem from the multiplicity of applications provided by the platform to be developed. These applications include: (1) Early stage disease detection, (2) Distinction between different stages of disease, remission and relapse (disease progression), (3) Assessing effects of therapeutic regimens and therapeutic monitoring, and (4) Identification of therapeutic targets for drug development (i.e. biomarker discovery). The universal platform provided by the plasma thermogram technology allows for the capability of detecting, diagnosing and monitoring a variety of very important diseases with high, unmet medical needs. This provides a multi-billion dollar opportunity for the commercialized plasma thermogram technology platform and diagnostic assays. This award is funded under the American Recovery and Reinvestment Act of 2009 (Public Law 111-5).

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government